▶ HEXARELIN · SUBTOPIC · MECHANISM
HEXARELIN Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Hexapeptide ghrelin receptor (GHS-R1a) agonist · the most potent GH-releasing activity in the GHRP class. Also engages the CD36 receptor on cardiomyocytes, the basis for documented preclinical cardioprotective signal independent of GH release.
PHARMACOKINETIC HALF-LIFE
Reported half-life for HEXARELIN: ~70 minutes. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
HEXARELIN is a defined sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
HEXARELIN is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
Cytoprotection is the protection of cells and tissues from injury via membrane stabilization, mitochondrial preservation, anti-apoptotic signaling, and counter-regulation of vascular failure. The pentadecapeptide BPC-157 is the most-studied cytoprotection-mediator peptide; its activity spans gastrointestinal, vascular, and multi-organ injury contexts.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Strongest GH-releasing activity in the GHRP class. Imbimbo 1994 characterized the pharmacology.
Bisi 1999 and subsequent studies report CD36-mediated cardioprotective signal independent of the GH-releasing arm.
Hexarelin produces faster GHS-R1a desensitization than other GHS with chronic administration in animal models.
MECHANISM Q+A
▶ What is hexarelin?
Hexarelin is a synthetic hexapeptide ghrelin / GHS-R1a receptor agonist with the strongest GH-releasing potency in the GHRP class. It also engages the CD36 receptor on cardiomyocytes, supporting a documented preclinical cardioprotective signal independent of the GH-releasing arm.
▶ Hexarelin vs ipamorelin · which is stronger?
Hexarelin has higher peak GH-releasing activity per dose. Ipamorelin has higher selectivity (no significant cortisol/prolactin elevation). Hexarelin's stronger pulse comes with stronger stress-hormone elevation and faster receptor desensitization with chronic dosing.
▶ What is the cardioprotective signal?
Hexarelin binds the CD36 scavenger receptor on cardiomyocytes (independent of the ghrelin receptor). Animal-model studies report reduced infarct size in ischemia-reperfusion models and preserved cardiac function. This is the only GHS with a documented direct cardioprotective mechanism.
▶ What is the half-life of hexarelin?
Approximately 70 minutes plasma half-life, longer than GHRP-2 and GHRP-6. Once-daily dosing is the typical research protocol.
▶ Why does hexarelin produce more cortisol than other GHRPs?
Hexarelin produces the strongest cortisol and ACTH elevation in the GHRP class via cross-reactivity at the central melanocortin and CRH-axis pathways. Ipamorelin selectivity avoids this signal; hexarelin's cortisol elevation is a known limitation.
▶ Does hexarelin cause receptor desensitization?
Yes. Chronic daily dosing produces faster GHS-R1a desensitization than other GHS in animal models. Research protocols typically use shorter cycles or pulsed dosing to preserve responsiveness.
CITED LITERATURE
- Imbimbo BP, Mant T, Edwards M, et al.. Hexarelin: A new growth hormone-releasing peptide. J Clin Endocrinol Metab 1994. link
- Bisi G, Podio V, Valetto MR, et al.. Hexarelin · A new GH-releasing peptide with cardiotropic activity. Eur J Endocrinol 1999. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25